The maximum retail price of 390 non-scheduled cancer medicines have been reduced by up to 87 percent, which would result in annual savings of around Rs 800 crore for the patients, the government said.
The National Pharmaceutical Pricing Authority on Feb. 27 had brought 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 percent.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Manufacturers and hospitals were directed to convey the revised MRP, to be effective from March 8, based on the trade margin formula.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
“The NPPA under Ministry of Chemicals and Fertilisers has put out list of 390 anti-cancer non-scheduled medicines with MRP reduction up to 87 percent. The revised prices would come into effect from March 8,” an official release said.
A total of 390 brands—that is 91 percent of the 426 brands reported by the manufacturers—showed downward price movement, it added.
This move is expected to benefit 22 lakh cancer patients in the country and would result in annual savings of around Rs 800 crore to the patients, the release said.
“The trade margin rationalisation for 42 anti-cancer drugs was rolled out as proof of concept, stressing on the new paradigm of self-regulation by the industry. The manufacturers of these 42 drugs have been directed not to reduce production volumes of brands under regulation,” it said.
While the MRP of 38 brands has been reduced by 75 percent and more, 124 brands have seen reduction between 50 percent to 75 percent.
The MRP of 121 brands has been reduced between 25 percent to 50 percent, while the maximum retail price of 107 brands have been reduced below 25 percent, the release said.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
